A retrospective evaluation of the combination of erenumab and onabotulinum toxin A for the prevention of chronic migraine
Source : https://www.sciencedirect.com/science/article/abs/pii/S0303846722000816?via=ihub
Prior to the approval of , (onabot A) was the only Food and Drug Administration-approved erenumab onabotulinum toxin A chronic migraine preventive treatment. In this study, we assess the safety...
Conclusion: This retrospective case series showed a reduction in monthly migraine and headache days with the treatment combination of erenumab and onabot A compared to onabot A alone in patients with chronic migraine.
-
Dr Hamid3yrMigraine is a common disabling primary headache disorder with high prevalence and significant socioeconomic burden and personal impacts.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrWe need to have this validated so that insurances are more open to covering it.
Show More Comments
Establishing content validity for the migraine Global Impression Item (mGI-I) assessment: a modified single-item migraine symptom severity questionnaire - BMC Neurology
Source : https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-022-02626-0
Objective To establish content validity of a single-item, migraine-specific symptom severity questionnaire for completion by migraine patients, key family members (KFMs) of migraine patients, and Healthcare Professionals (HCPs) who treat...
Conclusions: This qualitative study of 45 total respondents across 3 subpopulations, established the content validity and appropriateness of the mGI-I in migraine patients, KFMs, and migraine-treating HCPs. The study specifically confirmed that the mGI-I is comprehensive, easily understood and answered for each respondent population.
-
Dr Hamid3yrMigraine is a common disabling primary headache disorder with high prevalence and significant socioeconomic burden and personal impacts.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis is good to know.
Acute Medication Use in Patients With Migraine Treated With Monoclonal Antibodies Acting on the CGRP Pathway: Results From a Multicenter Study and Proposal of a New Index
Source : https://www.frontiersin.org/articles/10.3389/fneur.2022.846717/full
IntroductionAssessing the impact of migraine preventive treatments on acute medication consumption is important in clinical evaluation. The number of acute medication intakes per each monthly migraine day (MMD) could provide...
Conclusions: We confirmed that MoAbs acting on CGRP pathway decrease acute migraine medication consumption. We proposed a new index that can be easily applied in clinical practice to quantify migraine burden and its response to acute medication. Our index could help optimizing migraine acute treatment in clinical practice.
-
Dr Hamid3yrAssessing the impact of migraine preventive treatments on acute medication consumption is important in clinical evaluation
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis is encouraging since that is the goal of prevention.
Immunogenicity of erenumab: A pooled analysis of six placebo-controlled trials with long-term extensions - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35272533/
1 Clinical Immunology, Amgen Inc., South San Francisco, CA, USA. 2 Global Biostatistical Sciences, Amgen, Inc. Thousand Oaks, CA, USA. 3 Translational Safety and Bioanalytical Sciences, Amgen, Inc. Thousand Oaks,...
Conclusions: This pooled analysis showed that immunogenicity had no meaningful clinical impact on efficacy or safety of erenumab in patients with migraine
-
Dr Hamid3yrimmunogenicity had no meaningful clinical impact on efficacy or safety of erenumab in patients with migraine
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis is great summary of trials.
Be Smart to Identify the Stroke-Like Migraine Attacks After Radiation Therapy (SMART) Syndrome - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35273871/
Stroke-like migraine attacks after radiation therapy (SMART) are uncommon, often occurring years or decades after brain radiation therapy. This syndrome is a diagnosis of exclusion, and only about 40 cases...
Conclusion: Here we present the case of a 55-year-old man who experienced SMART nine years after radiation therapy and who was successfully treated with steroids.
-
Huma Sheikh, CEO, NY Neurology Medicine, PC3yrThis is an important phenomenon to be aware of.